

# Giuseppe Altavilla

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8679261/publications.pdf>

Version: 2024-02-01

29  
papers

5,499  
citations

623574

14  
h-index

477173

29  
g-index

31  
all docs

31  
docs citations

31  
times ranked

7181  
citing authors

#	ARTICLE	IF	CITATIONS
1	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2012, 13, 239-246.	5.1	4,943
2	Liquid biopsy for lung cancer early detection. <i>Journal of Thoracic Disease</i> , 2018, 10, S882-S897.	0.6	93
3	Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. <i>Lung Cancer: Targets and Therapy</i> , 2017, Volume 8, 109-125.	1.3	49
4	Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role. <i>Translational Lung Cancer Research</i> , 2015, 4, 728-42.	1.3	48
5	DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. <i>Pharmacogenomics Journal</i> , 2019, 19, 556-563.	0.9	35
6	Recent developments in the use of immunotherapy in non-small cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 781-798.	1.0	29
7	A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations. <i>Translational Lung Cancer Research</i> , 2021, 10, 1536-1556.	1.3	28
8	Targeted drugs in small-cell lung cancer. <i>Translational Lung Cancer Research</i> , 2016, 5, 51-70.	1.3	28
9	Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2047-2063.	2.0	26
10	Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases. <i>Journal of Neuro-Oncology</i> , 2008, 90, 31-33.	1.4	25
11	Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive. <i>Expert Review of Respiratory Medicine</i> , 2011, 5, 413-424.	1.0	24
12	Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2015, 9, 255-268.	1.0	24
13	Feasibility of cell-free circulating tumor DNA testing for lung cancer. <i>Biomarkers in Medicine</i> , 2016, 10, 417-430.	0.6	21
14	Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 713-722.	1.9	17
15	Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardioprotection, Italian Society of Cardiology (SIC). <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 406-415.	0.5	16
16	Necrotizing fasciitis as a rare complication of osteonecrosis of the jaw in a patient with multiple myeloma treated with lenalidomide: case report and review of the literature. <i>SpringerPlus</i> , 2014, 3, 123.	1.2	12
17	Incidence of nausea and vomiting in breast cancer patients treated with anthracycline plus cyclophosphamide-based chemotherapy regimens in Italy: NAVY observational study. <i>Supportive Care in Cancer</i> , 2018, 26, 4021-4029.	1.0	12
18	High-dose Radiotherapy for Oligo-progressive NSCLC Receiving EGFR Tyrosine Kinase Inhibitors: Real World Data. <i>In Vivo</i> , 2020, 34, 2009-2014.	0.6	12

#	ARTICLE	IF	CITATIONS
19	Second-line therapy of squamous non-small cell lung cancer: an evolving landscape. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 469-479.	1.0	11
20	Immunotherapeutic Advances for NSCLC. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 399-417.	3.0	9
21	Recent advances in epigenomics in NSCLC: real-time detection and therapeutic implications. <i>Epigenomics</i> , 2016, 8, 1151-1167.	1.0	8
22	Thyroid function, autoimmunity and nodules in hematological malignancies. <i>Archives of Endocrinology and Metabolism</i> , 2015, 59, 236-244.	0.3	6
23	Temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, S329-S333.	1.3	6
24	Efficacy, tolerability and impact on quality of life of clindamycin phosphate and benzoyl peroxide for the treatment of cetuximab-associated acneiform eruption in patients with metastatic colorectal cancer. <i>Journal of Dermatological Treatment</i> , 2016, 27, 148-152.	1.1	5
25	Capillary leak syndrome induced by neoadjuvant cisplatin and gemcitabine in a patient with bladder cancer. <i>Urology Case Reports</i> , 2021, 34, 101461.	0.1	5
26	Nail toxicities induced by liposomal doxorubicin: a retrospective case series. <i>European Journal of Dermatology</i> , 2017, 27, 434-435.	0.3	2
27	Prevalence of Use and Cost of Biological Drugs for Cancer Treatment: A 5-Year Picture from Southern Italy. <i>Clinical Drug Investigation</i> , 2018, 38, 269-278.	1.1	2
28	Radiation recall during cemiplimab therapy for locally advanced cutaneous squamous cell carcinoma. <i>Dermatologic Therapy</i> , 2020, 33, e14417.	0.8	2
29	Bone and lymph node metastases from occult mammary carcinoma: a case report of carcinoma of unknown primary (CUP) Syndrome. <i>BJR case Reports</i> , 2019, 5, 20190064.	0.1	0